Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | ALPI | P09923 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL7582135 | 1.00 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL27673609 | 0.96 | SLC7A5 (0.36) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL19209935 | 0.94 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL21331899 | 0.94 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL584583 | 0.94 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL584582 | 0.94 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL874925 | 0.93 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL874923 | 0.93 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL8819187 | 0.91 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL8819193 | 0.91 | SLC7A5 (0.38) | SLC7A5CYP3A4CYP1A2PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4332231-A2 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | Novartis AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| EP-3536776-B1 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20230323419-A1 | VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| EP-3212660-B1 | MAMMALIAN CELLS EXPRESSING CYTOMEGALOVIRUS ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-03-25 | — | — | EP | disclosed |
| US-10414802-B2 | Mammalian cells expressing cytomegalovirus antigens | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2019-09-17 | — | — | US | disclosed |
| EP-3536776-A1 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | Novartis AG (CH) | 2019-09-11 | — | — | EP | disclosed |
| EP-3137595-B1 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | NOVARTIS AG (CH) | 2019-03-13 | — | — | EP | disclosed |
| US-20170362278-A1 | MAMMALIAN CELLS EXPRESSING CYTOMEGALOVIRUS ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2017-12-21 | — | — | US | disclosed |
| EP-3212660-A1 | MAMMALIAN CELLS EXPRESSING CYTOMEGALOVIRUS ANTIGENS | GlaxoSmithKline Biologicals S.A. (BE) | 2017-09-06 | — | — | EP | disclosed |
| EP-3137595-A2 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | Novartis AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044587-A1 | Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| WO-2016067239-A1 | MAMMALIAN CELLS EXPRESSING CYTOMEGALOVIRUS ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-05-06 | — | — | WO | disclosed |
| EP-3015475-A1 | Mammalian cells expressing cytomegalovirus antigens | Novartis AG (CH) | 2016-05-04 | — | — | EP | disclosed |
| WO-2015166427-A2 | NOVEL VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | NOVARTIS AG (CH) | 2015-11-05 | — | — | WO | disclosed |
| WO-2011072833-A1 | A MUTANT SERINE PROTEASE AND A METHOD AND USES RELATING THERETO | ROCHE DIAGNOSTICS GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2004016752-A2 | PROTEOME-WIDE MAPPING OF POST-TRANSLATIONAL MODIFICATIONS USING ENDONUCLEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-1240352-A2 | MOLECULES DERIVED FROM MECHANISM BASED DRUG DESIGN | eXegenics Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001045836-A2 | MOLECULES DERIVED FROM MECHANISM BASED DRUG DESIGN | CYTOCLONAL PHARMACEUTICS, INC. (US) | 2001-06-28 | — | — | WO | disclosed |